Literature DB >> 1724996

Calcium-channel drugs: structure-function relationships and selectivity of action.

D J Triggle1.   

Abstract

Calcium channels are ubiquitously distributed in excitable cells. The calcium-channel antagonists interact specifically at the L subclass of channels to mediate cardiovascular effects. These channels may be considered as pharmacologic receptors with specific drug binding sites and subject to a variety of regulatory influences. Each site is specific for agents of the three principal structural classes--the phenylalkylamines, the 1,4-dihydropyridines, and the benzothiazepines--and each exhibits defined structure-activity relationships. The 1,4-dihydropyridine structure exhibits both potent antagonistic and activator properties. The calcium channel antagonists exhibit considerable selectivity of action in the cardiovascular system, both between and within structural groups. This selectivity has a variety of causes including voltage dependence of the interaction, whereby the apparent affinity of the antagonist is determined by the membrane potential and stimulus pattern. Experimental evidence underlying the structure-activity relationships and the voltage-dependent behavior of 1,4-dihydropyridines is reviewed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724996

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  16 in total

1.  Ca(v)1.2 splice variant with exon 9* is critical for regulation of cerebral artery diameter.

Authors:  Matthew A Nystoriak; Kentaro Murakami; Paul L Penar; George C Wellman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

2.  Alteration of loosely bound calcium in the guinea pig organ of Corti after treatment with diltiazem as calcium channel blocker.

Authors:  U R Heinrich; J Maurer; W Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

3.  Interactions between H+ and Ca2+ near cardiac L-type calcium channels: evidence for independent channel-associated binding sites.

Authors:  Y W Kwan; R S Kass
Journal:  Biophys J       Date:  1993-09       Impact factor: 4.033

4.  Differential potentiation by depolarization of the effects of calcium antagonists on contraction and Ca2+ current in guinea-pig heart.

Authors:  R Okuyama; S Adachi-Akahane; T Nagao
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

5.  Effects of mibefradil on intracellular Ca2+ release in cultured rat cardiac fibroblasts and human platelets.

Authors:  M Eberhard; K Miyagawa; K Hermsmeyer; P Erne
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

6.  Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries.

Authors:  K Bian; K Hermsmeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-08       Impact factor: 3.000

7.  Structural model for phenylalkylamine binding to L-type calcium channels.

Authors:  Ricky C K Cheng; Denis B Tikhonov; Boris S Zhorov
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

Review 8.  Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.

Authors:  W C Little; C P Cheng; L Elvelin; M Nordlander
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

Review 9.  Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?

Authors:  Thor Tejada; Alessia Fornoni; Oliver Lenz; Barry J Materson
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

10.  Dihydropyridines as inhibitors of capacitative calcium entry in leukemic HL-60 cells.

Authors:  Jacquie L Harper; Carol S Camerini-Otero; An Hu Li; Soon Ai Kim; Kenneth A Jacobson; John W Daly
Journal:  Biochem Pharmacol       Date:  2003-02-01       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.